Polycystic ovary syndrome (Q77919875)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9922912%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

review article

1 reference

title

Polycystic ovary syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9922912%20AND%20SRC:MED&resulttype=core&format=json

polycystic ovary syndrome

9 December 2019

main subject

1 reference

1 reference

A E Taylor

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9922912%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

publication date

1 December 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9922912%20AND%20SRC:MED&resulttype=core&format=json

Endocrinology and Metabolism Clinics of North America

9 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9922912%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9922912%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9922912%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

page(s)

877-902, ix

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9922912%20AND%20SRC:MED&resulttype=core&format=json

Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells

9 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Clinical review 56: Nonclassic adrenal hyperplasia: current concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Pituitary-Ovarian Relationships in Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Gonadotropin Levels and Secretory Patterns in Patients with Typical and Atypical Polycystic Ovarian Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Spironolactone and estrogen-progestin therapy for hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Vaginal progesterone administration in physiological doses normalizes raised luteinizing hormone levels in patients with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The role of oral contraceptives in the treatment of hyperandrogenic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Insulin resistance in nonobese patients with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Cellular mechanisms of insulin resistance in polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial**Supported in part by Schering-Plough, Pointe-Claire, Québec, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Spironolactone therapy in hypertrichosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Virilizing adrenocortical tumors in adult women. Report of 10 patients, 2 of whom each had a tumor secreting only testosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Identification of virilizing adrenal tumors in hirsute women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Detection of Functional Ovarian Hyperandrogenism in Women with Androgen Excess

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The ovarian androgen producing cells: a review of structure/function relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Clinical assessment of body hair growth in women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Serum testosterone concentrations in the evaluation of androgen-producing tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Changes in unbound sex steroids and sex hormone binding globulin--binding capacity during oral and vaginal progestogen administration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Decreased release of gonadotropin-releasing hormone during the preovulatory midcycle luteinizing hormone surge in normal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Monitoring techniques for improved pregnancy rates during clomiphene ovulation induction.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

3 alpha, 17 beta-androstanediol glucuronide in plasma. A marker of androgen action in idiopathic hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Circulating luteinizing hormone pulse frequency in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

A comparison of androgen production and clearance in hirsute and obese women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Classification of Secondary Amenorrhea Based on Distinct Hormonal Patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Obesity, serum steroid levels, and pulsatile gonadotropin secretion in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Characterization of intrafollicular steroid hormones, inhibin, and follistatin in women with and without polycystic ovarian syndrome following gonadotropin hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women**Supported in part by National Institutes of Health grant HD-17519-01A1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Adrenal and gonadal androgen secretion in normal females

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The effect of oral contraceptive treatment on the serum concentration of dehydroisoandrosterone sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The urinary excretion of interstitial-cell and follicle-stimulating hormone activity by women with diseases of the reproductive system

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Pathological mechanisms in polycystic ovary syndrome: modulation of LH pulsatility by progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Genotyping Steroid 21-Hydroxylase Deficiency: Hormonal Reference Data*

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Effects of obesity on gonadotropin secretion in patients with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Insulin resistance in patients with polycystic ovaries: its relationship to body weight and androgen levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The relative contributions of hepatic and peripheral tissues to insulin resistance in hyperandrogenic women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Spironolactone in combination drug therapy for unresponsive hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Polycystic ovaries--a common finding in normal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The impact of ovarian laser surgery on the gonadotrophin secretion in women with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Androgen and insulin response to an oral glucose challenge in hyperandrogenic women.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Absence of insulin receptor gene mutations in three insulin-resistant women with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Effects of increasing the frequency of low doses of gonadotropin-releasing hormone (GnRH) on gonadotropin secretion in GnRH-deficient men

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Luteinizing hormone excretion in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Effect of androgen on adrenal steroidogenesis in normal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Metabolic effects of combined cyproterone acetate and percutaneous 17 beta oestradiol after six and twelve months therapy in 61 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Clinical signs of androgen excess as risk factors for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

The polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Inappropriate Secretion of Follicle-Stimulating Hormone and Luteinizing Hormone in Polycystic Ovarian Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

Sex differences in the twenty-four-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970045-1

7 January 2021

10.1016/S0889-8529(05)70045-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9922912%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference